Regarding ATM inhibition in clinical settings, cancer patients with ATM gene mutation have benefited from ICB therapy compared to those with wild-type ATM gene [22,25,27,40,41,42], because ATM gene mutation is found to be correlated with TMB-H, dMMR, or the increased expression of PD-L1 [42,43], which are known biomarkers for responses to ICB therapy [9,10,11,12]. Here, ATM is linked to cancer.